Financials Belluscura plc

Equities

BELL

GB00BD3B8Z11

Medical Equipment, Supplies & Distribution

Delayed London S.E. Other stock markets 02:59:59 2024-05-02 am EDT			5-day change	1st Jan Change
7.25 ^GBX	0.00%		-3.33%	-68.48%

Apr. 02	Belluscura sees financial hit from delay to closing TMT acquisition	AN
Apr. 02	AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist	AN

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025
Capitalization ¹	172.5	97.46	14.94	14.94	-
Enterprise Value (EV) ¹	172.5	95.42	14.64	14.34	13.34
P/E ratio	-27.5 x	-11.7 x	-1.18 x	-3.35 x	5.17 x
Yield	-	-	-	-	-
Capitalization / Revenue	-	63.2 x	8.08 x	0.81 x	0.42 x
EV / Revenue	-	61.8 x	7.91 x	0.78 x	0.38 x
EV / EBITDA	-	-15.4 x	-2.14 x	-7.36 x	2.34 x
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Price to Book	-	-	-	-	-
Nbr of stocks (in thousands)	113,835	123,017	165,033	165,033	-
Reference price ²	1.515	0.7922	0.0905	0.0905	0.0905
Announcement Date	2/22/22	6/29/23	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2021	2022	2023	2024	2025
Net sales ¹	-	1.543	1.85	18.5	35.5
EBITDA ¹	-	-6.201	-6.85	-1.95	5.7
EBIT ¹	-	-8.129	-9.75	-3.8	2.95
Operating Margin	-	-526.84%	-527.03%	-20.54%	8.31%
Earnings before Tax (EBT) ¹	-	-8.153	-11.6	-4.35	2.4
Net income ¹	-5.213	-8.153	-11.6	-4.35	2.35
Net margin	-	-528.4%	-627.03%	-23.51%	6.62%
EPS ²	-0.0550	-0.0680	-0.0770	-0.0270	0.0175
Free Cash Flow	-	-	-	-	-
FCF margin	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	2/22/22	6/29/23	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 S1	2023 S2	2024 S1	2024 S2	2025 S1	2025 S2
Net sales ¹	-	2.3	8.4	12.1	16.8	24.1
EBITDA ¹	-	-3.6	-3.2	0.8	0.5	6.9
EBIT ¹	-	-4.5	-4	-0.1	-1.3	5.1
Operating Margin	-	-195.65%	-47.62%	-0.83%	-7.74%	21.16%
Earnings before Tax (EBT) ¹	-	-4.5	-4.1	-0.1	-1.3	5.1
Net income ¹	-6.419	-4.5	-4.1	-0.1	-1.3	5.1
Net margin	-	-195.65%	-48.81%	-0.83%	-7.74%	21.16%
EPS ²	-0.0520	-0.0300	-0.0300	-	-0.0100	0.0300
Dividend per Share	-	-	-	-	-	-
Announcement Date	9/13/23	-	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2021	2022	2023	2024	2025
Net Debt ¹	-	-	-	-	-
Net Cash position ¹	-	2.04	0.3	0.6	1.6
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow	-	-	-	-	-
ROE (net income / shareholders' equity)	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-	-
Assets ¹	-	-	-	-	-
Book Value Per Share	-	-	-	-	-
Cash Flow per Share	-	-	-	-	-
Capex ¹	-	5	3.3	3	2
Capex / Sales	-	324.16%	178.38%	16.22%	5.63%
Announcement Date	2/22/22	6/29/23	-	-	-

¹USD in Million

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Belluscura plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0905 USD

Average target price

0.4652 USD

Spread / Average Target

+413.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BELLUSCURA PLC	-68.48%	14.94M
ABBOTT LABORATORIES	-3.43%	184B
MEDTRONIC PLC	-1.81%	107B
BECTON, DICKINSON AND COMPANY	-4.15%	67.52B
DEXCOM, INC.	+1.43%	50.06B
CENCORA, INC.	+11.60%	45.67B
HOYA CORPORATION	+3.40%	41B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.03%	26.73B
WEST PHARMACEUTICAL SERVICES, INC.	+3.21%	26.47B
TERUMO CORPORATION	+15.23%	25.05B

Other Medical Equipment, Supplies & Distribution